SecBot SecBot
SECBOTREPLAY Home › Report › SANA

SANA · Sana Biotechnology reported Q2 2026 GAAP net loss of $63.6M…

Sana Biotechnology, Inc · PRESS-RELEASE filed Aug 10, 2026 at 16:05 ET

At the news

NEUTRALIMPACT 4/10

PRESS-RELEASE filed Aug 10, 2026 at 16:05 ET

Sana Biotechnology reported Q2 2026 GAAP net loss of $63.6M ($0.22/share), slightly narrower than the year-ago $93.8M loss ($0.39/share), driven by the absence of a $44.6M impairment and lower R&D spend. Non-GAAP net loss per share was $0.13, comparing favorably to $0.16 a year ago. The company ended Q2 with $160.5M cash, projecting runway into mid-2027 after raising $93.3M from ATM sales and Mayo Clinic equity investment. Key pipeline catalysts remain on track: SC451 IND/Phase 1/2 start for type 1 diabetes as early as this year, and first-in-human data for SG293 in non-Hodgkin lymphoma also expected this year.

  • Q2 2026 GAAP net loss $63.6M ($0.22/share) vs $93.8M ($0.39/share) in Q2 2025
  • Non-GAAP net loss $39.7M ($0.13/share) vs $38.9M ($0.16/share) a year ago
  • Cash, equivalents, and marketable securities $160.5M as of June 30, 2026; cash runway expected into mid-2027
  • Raised $93.3M in Q2 from ATM sales of common stock and Mayo Clinic equity investment

Replay the market's reaction

Step through every 5 minutes around the news, then see how it compares with similar events.

Subscribe for Full Access